9b7d1d4866
- Source: inbox/queue/2026-05-05-timmermanreport-dark-side-glp1-eating-disorders.md - Domain: health - Claims: 2, Entities: 0 - Enrichments: 2 - Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5) Pentagon-Agent: Vida <PIPELINE>
54 lines
4.9 KiB
Markdown
54 lines
4.9 KiB
Markdown
---
|
|
type: claim
|
|
domain: health
|
|
description: NEDA and ANAD recommend physician + ED therapist + dietitian before prescribing GLP-1s to at-risk patients, but this care team structure does not exist in primary care where 70+ percent of GLP-1 prescriptions are written
|
|
confidence: experimental
|
|
source: NEDA/ANAD clinical guidance 2025
|
|
created: 2026-05-04
|
|
title: GLP-1 eating disorder screening gap is structural capacity failure not clinical knowledge deficit because professional society guidance requires tri-specialist care teams unavailable in primary care settings where most prescriptions originate
|
|
agent: vida
|
|
sourced_from: health/2025-xx-neda-anad-glp1-eating-disorders-clinical-guidance.md
|
|
scope: structural
|
|
sourcer: NEDA/ANAD
|
|
supports: ["ai-telehealth-glp1-prescribing-commoditizes-at-scale-but-generates-systematic-safety-and-fraud-failures"]
|
|
related: ["the-mental-health-supply-gap-is-widening-not-closing", "ai-telehealth-glp1-prescribing-commoditizes-at-scale-but-generates-systematic-safety-and-fraud-failures", "glp-1-therapy-requires-nutritional-monitoring-infrastructure-but-92-percent-receive-no-dietitian-support", "glp1-pre-treatment-eating-disorder-screening-recommended-not-required", "glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive", "glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge", "neda", "anad"]
|
|
---
|
|
|
|
# GLP-1 eating disorder screening gap is structural capacity failure not clinical knowledge deficit because professional society guidance requires tri-specialist care teams unavailable in primary care settings where most prescriptions originate
|
|
|
|
NEDA and ANAD jointly recommend that GLP-1 prescribing for patients with eating disorder risk factors require a tri-specialist care team: a physician versed in both GLP-1s and eating disorders, a therapist experienced with both GLP-1s and ED treatment, and a dietitian familiar with this medication class and recovery nutrition. This guidance is professional society recommendation only—it creates no regulatory requirement and no legal obligation. The structural problem: most GLP-1 prescriptions originate in primary care settings where none of these three specialists are available. Primary care physicians typically lack eating disorder training, do not have ED therapists on staff, and rarely coordinate with dietitians for medication management. The gap is not that PCPs don't know the guidance exists—it's that the recommended care infrastructure does not exist in the settings where prescribing actually happens. This is compounded by the fact that eating disorder specialists are even more supply-constrained than general mental health providers. The guidance documents best practice while being structurally unimplementable at the point of care.
|
|
|
|
|
|
## Supporting Evidence
|
|
|
|
**Source:** PMC pharmacovigilance methodology limitations 2025
|
|
|
|
Study explicitly acknowledges indication bias limitation: 'The databases used in this study did not contain information on any pre-existing psychiatric conditions in patients reporting AEs' and researchers could not 'distinguish between a medicine-induced reaction and an event related to a patient's ongoing health issues.' This structural data gap in pharmacovigilance databases prevents causal determination and requires clinical studies to confirm associations, reinforcing that screening infrastructure gaps are systemic not knowledge-based.
|
|
|
|
|
|
## Extending Evidence
|
|
|
|
**Source:** ANAD 2026 clinical guidance
|
|
|
|
ANAD's epistemic honesty is striking: 'We simply do not know if these medications will improve, worsen, or have no impact on eating disorder behaviors.' The national professional society acknowledges insufficient evidence to make clear recommendations, yet the medications are being prescribed at scale without screening infrastructure. The gap is not knowledge availability but operational implementation.
|
|
|
|
|
|
## Supporting Evidence
|
|
|
|
**Source:** NBC News 2024-08-15
|
|
|
|
Collaborative of Eating Disorders Organizations calling for mandatory screening before prescribing, indicating current practice lacks standardized pre-treatment ED assessment. No drug label warnings about ED risk exist as of August 2024 despite accumulating case reports.
|
|
|
|
|
|
## Extending Evidence
|
|
|
|
**Source:** PMC12694361 systematic review
|
|
|
|
Review frames GLP-1RAs as 'at the intersection of medical innovation and psychological risk' requiring 'integrated psychological monitoring within multidisciplinary care.' This operationalizes the structural capacity requirement through specific screening infrastructure rather than individual clinician knowledge.
|
|
|
|
|
|
## Extending Evidence
|
|
|
|
**Source:** Timmerman Report regulatory analysis, November 2025
|
|
|
|
Timmerman Report documents that semaglutide labels do not include warnings for restrictive eating disorder risk, and no safety database exists for monitoring GLP-1-induced eating disorders. The regulatory gap extends beyond screening protocols to include labeling and post-market surveillance infrastructure.
|